Xenetic Biosciences(XBIO) - 2025 Q4 - Annual Report

Technology Development - The company reported a significant focus on advancing its DNase technology, which is aimed at improving outcomes for patients with solid tumors [11] - The company is focusing on advancing its DNase technology for treating solid tumors, aiming to improve outcomes of existing treatments by targeting neutrophil extracellular traps (NETs) [1] - The company plans to develop its proposed drug candidates and is seeking regulatory approval for these candidates, with an emphasis on innovative immune-oncology technologies [1] Financial Challenges - The company has never been profitable and may require substantial additional funding to achieve its goals, which could impact its operations [18] - The strategic review process is ongoing, with potential implications for the company's business operations and stock price [13] - The company may face difficulties in maintaining compliance with Nasdaq listing requirements, which could lead to delisting [18] Market and Competitive Environment - The market opportunities for the company's drug candidates may be limited, particularly for patients who have failed prior treatments [19] - The competitive environment remains challenging, with risks from competing technologies and products [18] - The commercial success of any pharmaceutical products will depend on market acceptance by physicians, patients, and third-party payors [18] Clinical Development Risks - The company is heavily reliant on third parties for clinical studies, which poses risks if these parties do not perform satisfactorily [19] - The company anticipates potential delays in clinical trials and regulatory approvals, which could hinder commercialization efforts [19] - The company may face challenges in enrolling patients for clinical studies, which could delay or prevent the development of its pharmaceutical products [18] Organizational Growth - The company is focused on retaining key personnel and expanding its organization to support growth [19] - The company is exploring collaborations to enhance its product development and commercialization strategies [11]